Epidermolysis Bullosa Dystrophica Clinical Trial
Official title:
Generation and Evaluation of Hand Therapy Devices for Epidermolysis Bullosa (GLOVE Project): Proof of Concept Study for a Dressing Glove
Epidermolysis Bullosa (EB) is a group of genetic conditions causing extensive, painful skin
blisters and wounds. Four main types of EB are recognised, which all affect the hands but
those patients usually requiring hand therapy interventions have Recessive Dystrophic EB
(RDEB).
The proof of concept study is part of the GLOVE (Generation and evaLuation Of hand therapy
deVices for Epidermolysis bullosa) project. The project aims (i) to develop two hand therapy
devices; a disposable dressing glove and splint glove to manage blisters, wounds and
contractures that occur on the hands of people with RDEB (ii) to design and implement the
Hand Therapy Online (HTO) electronic patient record system and (iii) to determine the cost
effectiveness of the devices and the HTO system.
The proof of concept study focuses on testing the clinical performance and cost effectiveness
of the dressing glove when compared with conventional dressings.
Recruited GLOVE participants will be invited to participate in the 14 week study, conducted
using a quasi-experimental, n-of-1 research design. Patients who have not participated in
GLOVE will also be invited to join. Participants will be asked to follow their usual dressing
regime for six weeks. At week 7, they will be given several pairs of dressing gloves to
replace their usual dressings, or starting to wear the glove if they avoid dressings normally
and familiarise themselves. If participants usually wear their gloves to maintain their web
spaces, they will wear these on top of the dressing glove to help assess compatibility.
Participants will provide feedback twice a week from week 7 on the dressing glove by
answering 12 questions (TELER indicators) validated in the Pilot study (REC no: 16/LO/1046)
using the HTO system. Data from the HTO system will be used by the Health Economist to
determine the dressing glove and HTO's cost effectiveness.
Principal research question/objective How effective is the disposable dressing glove when
compared with the normal dressings and bandages used by the participants with RDEB based on
12 validated patient outcomes indicators that measure observations of hand function, device
use, symptoms, and problems and limitations?
Secondary research questions Is the disposable dressing glove compatible with the SkinniesTM
Web Spacer glove or any other make of glove used by the participants with RDEB to maintain
their web spaces? Would you like to continue wearing the dressing glove? Is there anything
else you(the participants) would like to tell us about the dressing glove?
Study design and methodology Study Design The proof of concept study of the dressing glove
will be conducted using a quasi-experimental, n-of-1 research design drawn from the Medical
Research Council Guidance for the design of complex interventions (MRC 2008). The reason for
using this research design is due to a small sample of a small population of people with
Recessive Dystrophic Epidermolysis Bullosa (RDEB). In addition, hand deformities amongst
people with RDEB vary from one individual to another. Treatment and care also involve more
than one intervention administered concurrently, for example wounds dressings, web-spacer
gloves and splints. The researchers need to study the performance of these devices
individually and together in terms of their effectiveness in delaying disease progression
deformities.
The n-of-1 study design will enable investigation of the dressing glove performance against
pre-determined performance criteria (12 patient recorded outcome measures on the HTO system)
at the individual and group level with each participant acting as their own control.
Sample Size The sample for the GLOVE project is 14 participants. To date, seven adults and
six children from pre-school age to school age have been recruited to the project from the
project's two NHS sites, Guy's and St Thomas' (GSTT) NHS Foundation Trust and Great Ormond
Street Hospital (GOSH) NHS Foundation Trust respectively. All the GLOVE participants will be
invited to participate in the proof of concept study, subject to meeting the inclusion
criteria.
Method of Recruitment The EB clinical team (GSTT; GOSH) will identify potential participants
who meet the inclusion criteria for the study. The KCL research team will send a letter of
invitation to these participants containing age appropriate information sheets, assent and
consent forms (Letter of invitation V2 10 Jan 2017). The letter also has the contact details
for the King's College Research team should the participants require further information.
Participants will have a minimum of a week to decide if they would like to participate in the
study. They will be invited to return the reply slip to the EB clinicians who will return
them to the Chief Investigator. The EB clinicians will recruit and consent those participants
who have not be involved in the GLOVE project to date. Those who have will be recruited and
consented by the KCL research team. Adults (18 years and over) or their carers will be asked
to provide written informed consent. Children (7-17 years) will also be asked to provide
written informed consent. Their parents will also be asked to provide their written consent
for their child to participate. Children aged 4-6 will be invited to provide written assent,
once their parents have agreed to this. The parents will also provide their written consent,
as will the parents of babies and toddlers. The consent and assent forms will be returned to
the Chief Investigator at King's College London and kept in a locked cupboard, separated from
the data in order to maintain data anonymity.
Conduct of the Proof of Concept Study The study will take place over 14 weeks. Participants
will be asked to follow their usual dressing regime for six weeks. At week 7, they will be
given several pairs of dressing gloves to familiarise themselves with. At week 8,
participants will replace their usual dressings and bandages with the dressing glove or start
to wear the gloves if they avoid dressings normally. If participants usually wear their
gloves to maintain their web spaces, they will continue to wear these on top of the dressing
glove to help assess compatibility.
Method of data collection Participants will provide feedback twice a week on the dressing
glove by answering 12 questions (TELER indicators) using the Hand Therapy Online system
(HTO), which is an electronic patient record system (HTO indicators V2 10 Jan 2017; Patient
Guide V3). The indicators and the HTO were validated in the Pilot study (REC no: 16/LO/1046).
There are three types of measurements 1) TELER indicators, (2) physical measurements (3)
measures of cost. The TELER indicators are a tool to measure observations of hand function,
device use, symptoms and problems/limitations. The indicators measure clinically meaningful
changes comprising an improvement, deterioration or no change in hand function from one time
point to another. Each indicator is on a scale of six clinical steps or 'codes'. Code 5 is
best case scenario or the treatment goal and code 0 is worst case scenario (i.e. the problem
to be avoided) with codes 4, 3, 2 and 1 being clinically meaningful steps towards or away
from the treatment goal.
GLOVE participants recruited to the study will be trained by the KCL researchers to use HTO
system to provide feedback twice a week on the dressing glove by answering the TELER
indicators for the dressing glove validated in the pilot study (REC no: 16/LO/1046).
The data from the HTO system will inform the methodology for measuring the cost effectiveness
of the dressing glove.
Data analysis Numerical data analysis comprises automated calculation of patient specific
index numbers within the digitised system (Deficit Index, Improvement Index, Maintenance
Index, and Effectiveness Index) and two group indices (Health Status Index and Health Gain
Index). An analysis of the costs of standard care versus the intervention will also be
performed taking into account the use of products, time taken for wound care, and impact of
wound care on daily living.
Researcher bias will be minimised by their minimal direct contact with the data collection
process. In addition no attempt has been made to design out any confounding variables,
thereby replicating the situations in which patients are normally treated.
Report writing and dissemination The Chief Investigator will take responsibility for writing
the reports during the study and disseminating the findings, positive and negative, through
publications and conference presentations.
The findings from the study will enable generalisations to be made to the wider population of
RDEB patients with similar disease progression hand deformities that require the constant use
of wound dressing and web-spacer gloves (Research Protocol V2 10 Jan 2017.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01263379 -
Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa
|
Phase 1/Phase 2 | |
Completed |
NCT01716169 -
Treatment of Chronic and Non-Chronic Wounds in Patients With Recessive Dystrophic Epidermolysis Bullosa Using Helicoll Collagen Dressings Versus Standard of Care
|
N/A | |
Completed |
NCT00951964 -
Treatment of Epidermolysis Bullosa Dystrophica by Polyphenon E (Epigallocatechin 3 Gallate)
|
Phase 2 | |
Recruiting |
NCT03269474 -
Computational Drug Repurposing for All EBS Cases
|
||
Recruiting |
NCT01019148 -
Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa
|
||
Not yet recruiting |
NCT05390073 -
Growth Hormone in EB
|
||
Recruiting |
NCT04213703 -
A Pilot Study to Explore the Role of Gut Flora in Epidermolysis Bullosa
|
||
Not yet recruiting |
NCT06177353 -
Study of the Blood and Skin Immunological Profile of Patients With Recessive Dystrophic Epidermolysis Bullosa: in Vivo Analysis and the Impact of Placental Stem Cells in Vitro
|
||
Recruiting |
NCT06007235 -
CACIPLIQ20 in Wound Healing in Subjects With Epidermolysis Bullosa
|
N/A | |
Active, not recruiting |
NCT05843994 -
Artificial Intelligence Patient App for RDEB SCCs
|
||
Active, not recruiting |
NCT05033574 -
The State of Sexual Development in Children With Inherited Epidermolysis Bullosa
|
||
Completed |
NCT04908215 -
INM-755 (Cannabinol) Cream for Treatment of Epidermolysis Bullosa
|
Phase 2 | |
Terminated |
NCT00587223 -
Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB)
|
Phase 3 | |
Active, not recruiting |
NCT04171661 -
Self-Assembled Skin Substitute for the Treatment of Epidermolysis Bullosa
|
Early Phase 1 | |
Terminated |
NCT00533572 -
Recessive Dystrophic Epidermolysis Bullosa Screening for Possible Gene Transfer
|
N/A | |
Completed |
NCT00904163 -
Characteristics of Adult Patients With Recessive Dystrophic Epidermolysis Bullosa
|
N/A | |
Recruiting |
NCT03786237 -
Rigosertib for RDEB-SCC
|
Phase 1/Phase 2 |